ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 783

Outcome In Patients With Rheumatoid Disease: Simple Screening Tools Predict Cardiovascular Events and Death

Stefan Kleinert1, Margret Breunig2, Hans-Peter Tony3, Martin Feuchtenberger4, Marc Schmalzing5, Christian Kneitz6, Stefanie Lehmann7, Christiane Angermann7,8, Georg Ertl8 and Stefan Störk7, 1Rheumatology/Clinical Immunology,, University Hospital Würzburg, Würzburg, Germany, 2Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Wuerzburg, Germany, 3Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, 4Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, 5Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, 6Internal Medicine II, Hospital Südstadt, Rostock, Germany, 7Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany, 8Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, morbidity and mortality and risk assessment, NT-proBNP, Practice

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research I: Comorbidities in Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Patients with rheumatoid disease (RD) have an increased mortality risk compared to the normal population, mainly due to cardiovascular (CV) disease. Only a proportion of this risk increase seems explained by traditional cardiovascular risk factors. It is therefore difficult to identify patients with RD at high risk. We identified patients at increased risk for CV diseases and mortality by a screening program that is suitable for clinical practice in rheumatology, and quantified long-term outcome. Patients and Methods:

612 consecutive patients attending the rheumatology outpatient department of the University Hospital underwent a comprehensive CV risk assessment including medical history, patient questionnaires, ECG, and laboratory measurements including natriuretic peptides (NTproBNP). Screening was regarded “positive” if any of the following was present: European CV disease risk assessment Score (SCORE) ≥3% or NTproBNP≥200 pg/ml or any pathological ECG pattern. Patients were followed for a median of 5.5 years. Results:

312 subjects suffered from rheumatoid arthritis (RA; 80% female, mean age 54 yrs), and 260 from systemic autoimmune diseases (SAI; 77% female, mean age 51 yrs). Across all subjects, SCORE was ≥3% in 31%, 20% had a NTproBNP level ≥200 pg/ml, and 16% had a pathological ECG. All-cause mortality in RA/SAI was 6.2%/5.6%, respectively; frequency of cardiac events (ie, myocardial infarction, stroke, cardiac decompensation, resuscitation) was 5.8%/7.3%, respectively. The figure shows KM-plots for the 3 screening strategies, and unadjusted hazard ratios with 95%CI. In an age- and sex-adjusted multivariable model, only NTproBNP≥200 pg/ml conferred independent prognostic information with HR 2.8 (1.55-5.03; p<0.001) and an area under the ROC curve of 80%. Conclusion:

RD patients at high risk for death and CV events can be identified using simple screening tools. In patients with a SCORE ≥3% or NTproBNP ≥200 pg/ml are further diagnostics and closer long-term follow-up seem justified.

 

 


Disclosure:

S. Kleinert,
None;

M. Breunig,
None;

H. P. Tony,
None;

M. Feuchtenberger,
None;

M. Schmalzing,
None;

C. Kneitz,
None;

S. Lehmann,
None;

C. Angermann,
None;

G. Ertl,
None;

S. Störk,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcome-in-patients-with-rheumatoid-disease-simple-screening-tools-predict-cardiovascular-events-and-death/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology